Xiaoxia Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoxia Lu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Yi Yan
Department of Respiratory Medicine, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
3 shared publications - Ying Li
Department of Respiratory Medicine, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
3 shared publications - Di Liu
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
2 shared publications - Haizhou Liu
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
2 shared publications - Hebin Chen
Department of Respiratory Medicine, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
2 shared publications - Huaying Wang
Department of Respiratory Medicine, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
2 shared publications
Latest Publications
- Open Access
Scenario-Driven Rapid Testing for Top Pathogens in Pediatric Respiratory Infections: Clinical and Economic Value from Emergency Triage to Precision Anti-Infective Management in the PICU
Pediatric respiratory infections remain among the leading causes of emergency department visits, hospitalization and pediatric intensive care unit (PICU) admission. Although most acute respiratory infections in children are viral, clinical manifestations overlap substantially among viral, bacterial and atypical pathogens, creating diagnostic uncertainty and promoting empirical antimicrobial use. Rapid antigen tests, nucleic acid amplification tests, multiplex respiratory panels and metagenomic sequencing have expanded the ability to detect pathogens within clinically actionable timeframes. However, evidence from pediatric emergency trials indicates that rapid pathogen detection alone does not necessarily reduce antibiotic prescribing or healthcare costs. These findings suggest that the value of rapid diagnostics depends less on analytical breadth than on whether testing is applied to the right child, in the right clinical scenario and within a predefined decision pathway. This narrative review reorganizes the evidence around a scenario-driven top-pathogen framework. Top pathogens are defined as organisms that, in a specific age group, syndrome, season or care setting, have high prevalence, severe disease potential, transmissibility, treatment implications, antimicrobial resistance relevance or infection-control value. We discuss how top-pathogen testing should differ across emergency triage, inpatient ward management, severe pneumonia, PICU care, hospital-acquired pneumonia, ventilator-associated pneumonia and outbreak settings. We further examine the economic mechanisms through which rapid testing may generate value, including reduced unnecessary antibiotics, timely antiviral therapy, optimized isolation, shorter length of stay, reduced repeated testing and prevention of healthcare-associated transmission. Finally, we propose implementation principles centered on diagnostic stewardship, antimicrobial stewardship, local epidemiology and real-world cost-effectiveness evaluation. A scenario-driven top-pathogen strategy may provide a practical bridge between broad syndromic testing and precision infectious disease management in children.
Open AccessScenario-Driven Rapid Testing for Top Pathogens in Pediatric Respiratory Infections: Clinical and Economic Value from Emergency Triage to Precision Anti-Infective Management in the PICU
Pediatric respiratory infections remain among the leading causes of emergency department visits, hospitalization and pediatric intensive care unit (PICU) admission. Although most acute respiratory infections in children are viral, clinical manifestations overlap substantially among viral, bacterial and atypical pathogens, creating diagnostic uncertainty and promoting empirical antimicrobial use. Rapid antigen tests, nucleic acid amplification tests, multiplex respiratory panels and metagenomic sequencing have expanded the ability to detect pathogens within clinically actionable timeframes. However, evidence from pediatric emergency trials indicates that rapid pathogen detection alone does not necessarily reduce antibiotic prescribing or healthcare costs. These findings suggest that the value of rapid diagnostics depends less on analytical breadth than on whether testing is applied to the right child, in the right clinical scenario and within a predefined decision pathway. This narrative review reorganizes the evidence around a scenario-driven top-pathogen framework. Top pathogens are defined as organisms that, in a specific age group, syndrome, season or care setting, have high prevalence, severe disease potential, transmissibility, treatment implications, antimicrobial resistance relevance or infection-control value. We discuss how top-pathogen testing should differ across emergency triage, inpatient ward management, severe pneumonia, PICU care, hospital-acquired pneumonia, ventilator-associated pneumonia and outbreak settings. We further examine the economic mechanisms through which rapid testing may generate value, including reduced unnecessary antibiotics, timely antiviral therapy, optimized isolation, shorter length of stay, reduced repeated testing and prevention of healthcare-associated transmission. Finally, we propose implementation principles centered on diagnostic stewardship, antimicrobial stewardship, local epidemiology and real-world cost-effectiveness evaluation. A scenario-driven top-pathogen strategy may provide a practical bridge between broad syndromic testing and precision infectious disease management in children.
- Open Access
Respiratory Infection-Related Pathogens in the Pediatric Intensive Care Unit During 2019–2024 in Hubei, China
Respiratory infections are a leading cause of hospitalization and mortality in children, and the pediatric intensive care unit (PICU) is a critical setting for managing severe cases. However, the epidemiological patterns of respiratory pathogens in the PICU remain insufficiently characterized. In this retrospective study, we analyzed respiratory pathogen testing results from 2126 pediatric patients admitted to the PICU of Wuhan Children’s Hospital between 2019 and 2024. The pathogen spectrum and epidemiological characteristics were evaluated across age groups and seasons. Respiratory syncytial virus (RSV, 18.06%) was the most frequently detected viral pathogen, while Streptococcus pneumoniae (6.96%) was the predominant non-viral pathogen. The overall infection burden was highest in children aged ≤ 1 year (53.75%) and 3 < age ≤ 6 years (54.70%), indicating that early childhood represents a high-risk period for severe respiratory infections requiring intensive care. Pathogen distribution varied significantly across age groups. Distinct seasonal patterns were observed for several respiratory pathogens, particularly among viral pathogens, whereas non-viral pathogens showed more variable seasonal distributions. Furthermore, screening for 10 common pathogens accounted for 75% of PICU respiratory infections, highlighting the clinical utility of multiplex molecular detection. This study delineates the pathogen spectrum of respiratory tract infections in the PICU and characterizes their age- and season-specific epidemiological patterns. This study defines the pathogen spectrum and age- and season-specific patterns of respiratory infections in the PICU, providing evidence to support targeted pathogen surveillance, optimized multiplex diagnostics, and risk-informed infection control strategies in pediatric critical care.
Open AccessRespiratory Infection-Related Pathogens in the Pediatric Intensive Care Unit During 2019–2024 in Hubei, China
Respiratory infections are a leading cause of hospitalization and mortality in children, and the pediatric intensive care unit (PICU) is a critical setting for managing severe cases. However, the epidemiological patterns of respiratory pathogens in the PICU remain insufficiently characterized. In this retrospective study, we analyzed respiratory pathogen testing results from 2126 pediatric patients admitted to the PICU of Wuhan Children’s Hospital between 2019 and 2024. The pathogen spectrum and epidemiological characteristics were evaluated across age groups and seasons. Respiratory syncytial virus (RSV, 18.06%) was the most frequently detected viral pathogen, while Streptococcus pneumoniae (6.96%) was the predominant non-viral pathogen. The overall infection burden was highest in children aged ≤ 1 year (53.75%) and 3 < age ≤ 6 years (54.70%), indicating that early childhood represents a high-risk period for severe respiratory infections requiring intensive care. Pathogen distribution varied significantly across age groups. Distinct seasonal patterns were observed for several respiratory pathogens, particularly among viral pathogens, whereas non-viral pathogens showed more variable seasonal distributions. Furthermore, screening for 10 common pathogens accounted for 75% of PICU respiratory infections, highlighting the clinical utility of multiplex molecular detection. This study delineates the pathogen spectrum of respiratory tract infections in the PICU and characterizes their age- and season-specific epidemiological patterns. This study defines the pathogen spectrum and age- and season-specific patterns of respiratory infections in the PICU, providing evidence to support targeted pathogen surveillance, optimized multiplex diagnostics, and risk-informed infection control strategies in pediatric critical care.
- Open Access
Genomic Evolution of Influenza A(H1N1)pdm09 and A/H3N2 Viruses Among Children in Wuhan, China, Spanning the COVID-19 Pandemic (2020–2023)
Despite the persistent global threat of seasonal influenza viruses such as A(H1N1)pdm09 and A/H3N2, their epidemiological and genetic characteristics in China following the implementation of COVID-19 non-pharmaceutical interventions (NPIs) remain poorly characterized. Between September 2020 and December 2023, we conducted an integrated epidemiological and genomic analysis of influenza A viruses in children in Wuhan. The overall positivity rate for influenza A virus was markedly low at 3.43% (109/3171), reflecting a profound suppression of circulation during the pandemic. Among genotyped positives, H1N1pdm09 was predominant (52.3%), followed by H3N2 (16.5%) and untypeable strains (32.1%). Preschool children showed the highest susceptibility. Phylogenetic analysis revealed that the circulating H1N1 strains (90%) belonged to clade 6B.1A.5a.2, clustering with viruses from Hong Kong and Pakistan. In contrast, H3N2 strains (76.92%) primarily fell into clade 3C.2a1b.2a.2b, closely related to contemporary strains from Europe and North America. Notably, we identified key hemagglutinin mutations associated with antigenic drift (e.g., R240Q in H1N1; E78G, R158G in H3N2) and neuraminidase mutations potentially conferring antiviral resistance (e.g., S247N in H1N1; S245N, a putative novel glycosylation site, in H3N2). Evidence of reassortment events was also detected, underscoring the continued genomic evolution of these viruses despite their low prevalence. Our findings demonstrate that genetically diverse and antigenically drifted influenza A viruses continued to circulate and evolve in Wuhan during the COVID-19 pandemic, albeit at dramatically reduced levels. This highlights the critical need for sustained genomic surveillance and timely updates of vaccine compositions to pre-empt the resurgence of influenza in the post-pandemic era.
Open AccessGenomic Evolution of Influenza A(H1N1)pdm09 and A/H3N2 Viruses Among Children in Wuhan, China, Spanning the COVID-19 Pandemic (2020–2023)
Despite the persistent global threat of seasonal influenza viruses such as A(H1N1)pdm09 and A/H3N2, their epidemiological and genetic characteristics in China following the implementation of COVID-19 non-pharmaceutical interventions (NPIs) remain poorly characterized. Between September 2020 and December 2023, we conducted an integrated epidemiological and genomic analysis of influenza A viruses in children in Wuhan. The overall positivity rate for influenza A virus was markedly low at 3.43% (109/3171), reflecting a profound suppression of circulation during the pandemic. Among genotyped positives, H1N1pdm09 was predominant (52.3%), followed by H3N2 (16.5%) and untypeable strains (32.1%). Preschool children showed the highest susceptibility. Phylogenetic analysis revealed that the circulating H1N1 strains (90%) belonged to clade 6B.1A.5a.2, clustering with viruses from Hong Kong and Pakistan. In contrast, H3N2 strains (76.92%) primarily fell into clade 3C.2a1b.2a.2b, closely related to contemporary strains from Europe and North America. Notably, we identified key hemagglutinin mutations associated with antigenic drift (e.g., R240Q in H1N1; E78G, R158G in H3N2) and neuraminidase mutations potentially conferring antiviral resistance (e.g., S247N in H1N1; S245N, a putative novel glycosylation site, in H3N2). Evidence of reassortment events was also detected, underscoring the continued genomic evolution of these viruses despite their low prevalence. Our findings demonstrate that genetically diverse and antigenically drifted influenza A viruses continued to circulate and evolve in Wuhan during the COVID-19 pandemic, albeit at dramatically reduced levels. This highlights the critical need for sustained genomic surveillance and timely updates of vaccine compositions to pre-empt the resurgence of influenza in the post-pandemic era.